Wockhardt's Zaynich antibiotic enables successful liver transplant for US cancer patient, shares soar, Phase III study nears ...

Wockhardt stock gained 10% to touch Rs 1,536.40; it has outperformed the market by zooming 262% thus far in calendar year ...

The new drug combines a well-established beta-lactam antibiotic – cefepime – with a new beta-lactamase inhibitor designed to overcome a key resistance mechanism that allows pathogens to ...

The FDA has given the green light to Exblifep, based on long-established beta-lactam antibiotic cefepime and a new extended-spectrum beta-lactamase inhibitor (BLI) called enmetazobactam ...

Wockhardt's share price touched upper circuit level of 10 per on NSE (National Stock Exchange), after company's exchange ...

Across India, at least 30 critically ill patients infected with multidrug-resistant (MDR) or extreme drug-resistant (XDR) bacteria that don’t respond to even last-line antibiotics — also called superb ...

The frequency of neutropenia in patients receiving long-term cefepime therapy for osteomyelitis compared with that in patients receiving other antimicrobials was studied. A comparative case review ...

Wockhardt Pharma shares hit the 10% upper circuit on Monday, December 16, reaching Rs 1,536.40—its highest level in nine ...

India needs new drugs, improve infection control practices to thwart AMR: Dr Prabhu Vinayagam: Nandita Vijayasimha Bengaluru Monday, December 16, 2024, 08:00 Hrs [IST] India needs ...

Having urinary tract infection (UTI) symptoms after antibiotics may mean the antibiotics were not taken properly, you have an antibiotic-resistant strain, a different antibiotic was needed, or you ...